We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
Read MoreHide Full Article
Key Takeaways
Danaher is expected to report Q2 revenues of $6.08 billion, up 2.4% year over year.
DHR's Biotechnology segment is projected to grow 5.5%, supported by bioprocessing demand.
Danaher's Masimo acquisition expanded its diagnostics portfolio, while costs and debt remain headwinds.
Danaher Corporation (DHR - Free Report) is scheduled to release second-quarter 2026 results on July 21, before market open.
The Zacks Consensus Estimate for revenues is pegged at $6.09 billion, which indicates an increase of 2.6% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.84 per share, which has increased a penny in the past seven days. The estimate indicates an increase of 2.2% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 6.7%.
Let’s see how things have shaped up for Danaher this earnings season.
Key Factors and Estimates for Q2
Strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in Western Europe and China, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid momentum in the medical filtration and research consumables business. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.95 billion, indicating a 5.5% rise from the year-ago reported number.
Strength in the clinical diagnostics businesses, led by growth in clinical lab and pathology diagnostics units, is expected to drive the Diagnostics segment’s results. However, softness in the molecular diagnostics business due to sluggish demand for respiratory tests is likely to have been a spoilsport. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.33 billion, indicating a 0.7% rise from the year-ago reported number.
Solid momentum in filtration and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.79 billion, indicating a 0.8% rise from the year-ago reported number.
In June 2026, Danaher acquired Masimo Corp. for $9.9 billion. The addition of Masimo’s advanced sensor technology and AI-enabled monitoring enabled Danaher to enhance its diagnostics portfolio. The buyout is expected to have boosted DHR’s performance during the quarter.
However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR’s bottom line in the to-be-reported quarter. Also, higher interest expenses associated with the company’s high debt are likely to prove detrimental to its profitability in the quarter.
Our proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as elaborated below.
Earnings ESP: Danaher has an Earnings ESP of +0.62% as the Most Accurate Estimate is pegged at $1.85 per share, which is higher than the Zacks Consensus Estimate of $1.84. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11.
Cardinal Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 10.3%.
CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on Aug. 5.
CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 16.8%.
West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2026 results on July 23.
West Pharmaceutical’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.4%.
View the Zacks #1 Rank List
Image: Bigstock
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
Key Takeaways
Danaher Corporation (DHR - Free Report) is scheduled to release second-quarter 2026 results on July 21, before market open.
The Zacks Consensus Estimate for revenues is pegged at $6.09 billion, which indicates an increase of 2.6% from the year-ago quarter’s figure. The consensus mark for earnings is pinned at $1.84 per share, which has increased a penny in the past seven days. The estimate indicates an increase of 2.2% from the figure reported in the year-ago quarter. The company’s bottom line surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average beat being 6.7%.
Let’s see how things have shaped up for Danaher this earnings season.
Key Factors and Estimates for Q2
Strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in Western Europe and China, is expected to have aided the Biotechnology segment. The segment’s performance is also likely to have benefited from solid momentum in the medical filtration and research consumables business. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.95 billion, indicating a 5.5% rise from the year-ago reported number.
Strength in the clinical diagnostics businesses, led by growth in clinical lab and pathology diagnostics units, is expected to drive the Diagnostics segment’s results. However, softness in the molecular diagnostics business due to sluggish demand for respiratory tests is likely to have been a spoilsport. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $2.33 billion, indicating a 0.7% rise from the year-ago reported number.
Solid momentum in filtration and consumables businesses is likely to have boosted the performance of the Life Sciences segment in the quarter. For the second quarter, the Zacks Consensus Estimate for the segment’s total sales is pegged at $1.79 billion, indicating a 0.8% rise from the year-ago reported number.
In June 2026, Danaher acquired Masimo Corp. for $9.9 billion. The addition of Masimo’s advanced sensor technology and AI-enabled monitoring enabled Danaher to enhance its diagnostics portfolio. The buyout is expected to have boosted DHR’s performance during the quarter.
However, the escalating costs and operating expenses, due to increasing input costs and product mix changes, are likely to have weighed on DHR’s bottom line in the to-be-reported quarter. Also, higher interest expenses associated with the company’s high debt are likely to prove detrimental to its profitability in the quarter.
Danaher Corporation Price and EPS Surprise
Danaher Corporation price-eps-surprise | Danaher Corporation Quote
Earnings Whispers
Our proven model predicts an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is the case here, as elaborated below.
Earnings ESP: Danaher has an Earnings ESP of +0.62% as the Most Accurate Estimate is pegged at $1.85 per share, which is higher than the Zacks Consensus Estimate of $1.84. You can uncover the best stocks before they’re reported with our Earnings ESP Filter.
Zacks Rank: DHR currently carries a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks to Consider
Here are some other companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank of 2 at present. The company is slated to release fourth-quarter fiscal 2026 results on Aug. 11.
Cardinal Health’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 10.3%.
CVS Health (CVS - Free Report) has an Earnings ESP of +1.42% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on Aug. 5.
CVS Health’s earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 16.8%.
West Pharmaceutical Services (WST - Free Report) has an Earnings ESP of +1.09% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2026 results on July 23.
West Pharmaceutical’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 19.4%.